

Anti-ERBB3/HER3 Antibody (Patritumab)

Introduction



Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody against ERBB3. Patritumab has a synergistic effect with Cetuximab and can effectively inhibit the phosphorylation of EGFR, HER2, HER3, ERK and AKT. Patritumab can also induce apoptosis and inhibit the growth of pancreatic, non-small cell lung cancer and colorectal cancer xenograft tumors.

Product parameters

| Alternative Names | U3-1287, AMG-888 |
|------------------------------|---|
| Target Accession | P21860 |
| Target | ERBB3 / HER3 |
| CAS number | 1262787-83-6 |
| Molecular Weight | 146.86 kDa |
| Host | сно |
| Reactivity | Human, Rat |
| Conjugation | Unconjugated |
| Form | Liquid |
| Concentration | See label |
| Buffer System | 100 mM Pro 20 mM Arg pH 5.0. No preservative! |
| Clonality | Monoclonal |
| Purification | Protein A |
| Isotype | IgG1 |
| Application | ELISA, FACS, Kinetics, Functional assay, Animal Model |
| Biological activity | Immobilized human HER3 His at 2 ug/mL can bind Anti-ERBB3/HER3 Antibody (Patritumab), EC50=0.04264 ug/mL. |
| Endotoxin | Less than 0.1 EU/ug determined by LAL method. |
| St <mark>eriliza</mark> tion | 0.2 μM filtered |
| Reconstitution | For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration Gently shake it to solubilize the protein completely. Do not vortex. |
| Shipping | Dry ice |
| Storage | -80°C |
| Expiration Date | 2 years |
| Note | Please avoid freeze-thaw cycles. |

Note

1. This product is for scientific research use only.







